These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 6301258

  • 21. The treatment of locally advanced head and neck cancer with misonidazole, hyperbaric oxygen and irradiation: an interim report.
    Sealy R, Cridland S.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1721-3. PubMed ID: 6384161
    [Abstract] [Full Text] [Related]

  • 22. Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group.
    Van den Bogaert W, van der Schueren E, Van Tongelen C, Horiot JC, Chaplain G, Arcangeli G, Gonzalez D, Svoboda V.
    Radiother Oncol; 1985 Feb; 3(2):139-44. PubMed ID: 3983422
    [Abstract] [Full Text] [Related]

  • 23. Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck.
    Panis X, Nguyen TD, Froissart D, Demange L.
    Int J Radiat Oncol Biol Phys; 1984 Oct; 10(10):1845-9. PubMed ID: 6386760
    [Abstract] [Full Text] [Related]

  • 24. [Esophageal carcinoma: the final results of a multicenter and controlled German study with misonidazole and radiation].
    Scherer E, Bamberg M, Godehard E, Calcanis A, Brust V, Herbst M, Karstens JH, Kleibel F, Makoski HB, Prignitz R.
    Strahlenther Onkol; 1986 Nov; 162(11):661-6. PubMed ID: 3538460
    [Abstract] [Full Text] [Related]

  • 25. A report on misonidazole in randomized trial in locally advanced head and neck cancer.
    Sealy R, Williams A, Cridland S, Stratford M, Minchinton A, Hallet C.
    Int J Radiat Oncol Biol Phys; 1982 Nov; 8(3-4):339-42. PubMed ID: 7050035
    [Abstract] [Full Text] [Related]

  • 26. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.
    Fazekas J, Pajak TF, Wasserman T, Marcial V, Davis L, Kramer S, Rotman M, Stetz J.
    Int J Radiat Oncol Biol Phys; 1987 Aug; 13(8):1155-60. PubMed ID: 3301758
    [Abstract] [Full Text] [Related]

  • 27. Experience in the radical radiotherapy of cancer in the bilharzial bladder: the use of misonidazole.
    Awwad HK, Akhoush H, El-Merzabani M, El Badawy S, Barsoum M, el Baki HA.
    Radiother Oncol; 1984 Jun; 2(1):1-8. PubMed ID: 6095372
    [Abstract] [Full Text] [Related]

  • 28. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).
    Lee DJ, Pajak TF, Stetz J, Order SE, Weissberg JB, Fischer JJ.
    Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):465-70. PubMed ID: 2646255
    [Abstract] [Full Text] [Related]

  • 29. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
    Van den Bogaert W, van der Schueren E, Horiot JC, De Vilhena M, Schraub S, Svoboda V, Arcangeli G, de Pauw M, Van Glabbeke M.
    Radiother Oncol; 1995 May; 35(2):91-9. PubMed ID: 7569030
    [Abstract] [Full Text] [Related]

  • 30. A preliminary clinical study in the use of misonidazole in cancer of the head and neck.
    Sealy R.
    Br J Cancer Suppl; 1978 Jun; 3():314-7. PubMed ID: 277253
    [Abstract] [Full Text] [Related]

  • 31. The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: an RTOG pilot study (#78-02).
    Fazekas JT, Goodman RL, McLean CJ.
    Int J Radiat Oncol Biol Phys; 1981 Dec; 7(12):1703-8. PubMed ID: 7333912
    [No Abstract] [Full Text] [Related]

  • 32. Clinical experience with misonidazole: high dose fractions versus daily low doses.
    Kogelnik HD.
    Cancer Clin Trials; 1980 Dec; 3(2):179-86. PubMed ID: 6253098
    [Abstract] [Full Text] [Related]

  • 33. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
    Walker MD, Strike TA.
    Cancer Clin Trials; 1980 Dec; 3(2):105-9. PubMed ID: 6253094
    [Abstract] [Full Text] [Related]

  • 34. Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer.
    van den Bogaert W, van der Schueren E, Horiot JC, Chaplain G, Devilhena M, Raposo S, Leonor J, Schraub S, Chenal C, Barthelme E.
    Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):587-91. PubMed ID: 3516953
    [Abstract] [Full Text] [Related]

  • 35. Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer.
    Sealy R, Cridland S, Barry L, Norris R.
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1343-6. PubMed ID: 3531113
    [Abstract] [Full Text] [Related]

  • 36. Misonidazole in patients receiving radical radiotherapy: pharmacokinetic effects of phenytoin, tumor response and neurotoxicity.
    Moore JL, Paterson IC, Dawes PJ, Henk JM.
    Int J Radiat Oncol Biol Phys; 1982 Aug; 8(3-4):361-4. PubMed ID: 7107352
    [Abstract] [Full Text] [Related]

  • 37. Misonidazole and unconventional radiation in advanced squamous cell carcinoma of the esophagus: a phase II study of the Radiation Therapy Oncology Group.
    Ydrach AA, Marcial VA, Parsons J, Concannon J, Asbell SO, George F.
    Int J Radiat Oncol Biol Phys; 1982 Aug; 8(3-4):357-9. PubMed ID: 6809704
    [Abstract] [Full Text] [Related]

  • 38. Misonidazole combined with radiotherapy in the treatment of inoperable squamous cell carcinoma of the lung. A double-blind randomized trial.
    Panduro J, Kjaer M, Wolff-Jensen J, Hansen HH.
    Cancer; 1983 Jul 01; 52(1):20-4. PubMed ID: 6303553
    [Abstract] [Full Text] [Related]

  • 39. Misonidazole combined with hyperfractionation in the management of malignant glioma.
    Fulton DS, Urtasun RC, Shin KH, Geggie PH, Thomas H, Muller PJ, Moody J, Tanasichuk H, Mielke B, Johnson E.
    Int J Radiat Oncol Biol Phys; 1984 Sep 01; 10(9):1709-12. PubMed ID: 6090367
    [Abstract] [Full Text] [Related]

  • 40. Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.
    Cottrill CP, Bishop K, Walton MI, Henk JM.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):807-10. PubMed ID: 9845101
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.